-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Head and neck squamous cell carcinoma (of HNSCC) originated in the upper respiratory digestive tract mucosal epithelial tumors
Digestive infection
The RESGEX study is a randomized phase II trial that aims to compare the anti-epidermal growth factor receptor (anti-EGFR) antibody Tomuzotuximab (tomutuximab) and cetuximab (Cetuximab) in combination with chemotherapy for relapse and/ Or the efficacy and safety of first-line treatment of metastatic head and neck squamous cell carcinoma
In this study, 240 eligible patients were randomly divided into two groups and received Tomuzotuximab + cisplatin + fluorouracil or cetuximab + cisplatin + fluorouracil treatment.
(A) Progression-free survival (PFS) of the two groups; (B) Overall survival (OS) of the two groups
(A) Progression-free survival (PFS) of the two groups; (B) Overall survival (OS) of the two groupsThe median progression-free survival of the Tomuzotuximab group and the cetuximab group were 6.
The median progression-free survival of the Tomuzotuximab group and the cetuximab group were 6.
PFS and OS of patients grouped by p16 status
PFS and OS of patients grouped by p16 statusIn the exploratory analysis, the OS of the p16-positive subgroup was significantly longer than that of the p16-negative subgroup (hazard ratio 1.
The OS of the p16-positive subgroup was significantly longer than that of the p16-negative subgroup .
Compared with cetuximab, Tomuzotuximab as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma failed to improve the clinical prognosis of patients
Original source:
Original source:Klinghammer K, Fayette J, Kawecki A et al.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and / or metastatic squamous cell cancer of the head and neck - the RESGEX study
in this message